Capricor Therapeutics Inc Share Price Today: Live Updates & Key Insights

Capricor Therapeutics Inc share price today is $29.45, up -6.64%. The stock opened at $31 against the previous close of $31.17, with an intraday high of $31.91 and low of $29.105.

Capricor Therapeutics Inc Share Price Chart

Capricor Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Capricor Therapeutics Inc Share Price Performance

$29.45 -0.0664(-6.64%) CAPR at 23 Mar 2026 12:22 PM Biotechnology
Lowest Today 29.105
Highest Today 31.91
Today’s Open 31
Prev. Close 31.17
52 Week High 40.37
52 Week Low 4.30
Day’s Range: Low 29.105 High 31.91
52-Week Range: Low 4.30 High 40.37
1 day return -
1 Week return -4.5
1 month return +4.82
3 month return -1.25
6 month return +376.14
1 year return +119.26
3 year return +577.67
5 year return +455.04
10 year return -

Capricor Therapeutics Inc Institutional Holdings

BlackRock Inc 5.00

Vanguard Group Inc 4.47

Suvretta Capital Management, LLC 3.11

RA Capital Management, LLC 2.63

Vanguard Total Stock Mkt Idx Inv 2.55

Geode Capital Management, LLC 1.77

iShares Russell 2000 ETF 1.64

FMR Inc 1.61

Citadel Advisors Llc 1.57

State Street Corp 1.40

Millennium Management LLC 1.19

J. Goldman & Co LP 1.04

Morgan Stanley - Brokerage Accounts 0.96

Vanguard Institutional Extnd Mkt Idx Tr 0.87

DG Capital Management, LLC 0.72

NATIONAL BANK OF CANADA /FI/ 0.69

Fidelity Select Pharmaceuticals Port 0.68

JPMorgan Chase & Co 0.66

Fidelity Small Cap Index 0.66

Balyasny Asset Management LLC 0.62

Northern Trust Corp 0.61

Boxer Capital Management, LLC 0.57

iShares Russell 2000 Growth ETF 0.56

Fidelity Select Biotechnology 0.55

Ikarian Capital, LLC 0.46

RTW INVESTMENTS, LLC 0.44

Fidelity Extended Market Index 0.42

State St Russell Sm/Mid Cp® Indx SL Cl I 0.40

Woodline Partners LP 0.38

Strategic Advisers Fidelity US TtlStk 0.33

JPM Thematics Genetic Thrps C2 dist USD 0.33

Vanguard Russell 2000 ETF 0.32

Eastern Shore Small Cap Equity 0.26

State St Russell Sm Cap® Indx SL Cl I 0.23

Blackrock Extended Mkt Fund CF 0.20

iShares Micro-Cap ETF 0.18

Extended Equity Market Fund K 0.17

Schwab Small Cap Index 0.17

NT R2000 Index Fund - NL 0.15

Fidelity Total Market Index 0.15

Capricor Therapeutics Inc Market Status

Strong Buy: 5

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Capricor Therapeutics Inc Fundamentals

Market Cap 1669.49 M

PB Ratio 5.4633

PE Ratio 0.0

Enterprise Value 1586.62 M

Total Assets 355.95 M

Volume 5760601

Capricor Therapeutics Inc Company Financials

Annual Revenue FY23:14049880 14.0M, FY22:2548918 2.5M, FY21:244898 0.2M, FY20:310250 0.3M, FY19:1005028 1.0M

Annual Profit FY23:null 0.0M, FY22:2548918 2.5M, FY21:244898 0.2M, FY20:310250 0.3M, FY19:1005028 1.0M

Annual Net worth FY23:-29246365 -29.2M, FY22:-29018854 -29.0M, FY21:-19409108 -19.4M, FY20:-13480195 -13.5M, FY19:-7377790 -7.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:2261642 2.3M, Q2/2024:3971438 4.0M

Quarterly Profit Q3/2025:-20359098 -20.4M, Q2/2025:-22047254 -22.0M, Q1/2025:-18915572 -18.9M, Q3/2024:2261642 2.3M, Q2/2024:3614503 3.6M

Quarterly Net worth Q3/2025:-24570647 -24.6M, Q2/2025:-25910791 -25.9M, Q1/2025:-24391594 -24.4M, Q3/2024:-12556728 -12.6M, Q2/2024:-10999782 -11.0M

About Capricor Therapeutics Inc & investment objective

Company Information Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 231

Industry Biotechnology

CEO Dr. Linda Marbán Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Capricor Therapeutics Inc FAQs

What is the share price of Capricor Therapeutics Inc today?

The current share price of Capricor Therapeutics Inc is $29.45.

Can I buy Capricor Therapeutics Inc shares in India?

Yes, Indian investors can buy Capricor Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Capricor Therapeutics Inc shares in India?

You can easily invest in Capricor Therapeutics Inc shares from India by:

Can I buy fractional shares of Capricor Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Capricor Therapeutics Inc?

Capricor Therapeutics Inc has a market cap of $1669.49 M.

In which sector does Capricor Therapeutics Inc belong?

Capricor Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Capricor Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Capricor Therapeutics Inc?

The PE ratio of Capricor Therapeutics Inc is N/A and the PB ratio is 5.46.